SLS (SELLAS Life Sciences Group) Ending Cash Position: $107.20 Mil (As of Mar. 2026)


SLS SELLAS Life Sciences Group Inc SLS
25 GF Score
Price $13.95
! 1 Warning Sign
View Full Analysis

What is SELLAS Life Sciences Group Ending Cash Position?

SELLAS Life Sciences Group SLS -6.94% 25 Ending Cash Position is $107.20 Mil as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

SELLAS Life Sciences Group's Ending Cash Position for the quarter that ended in Mar. 2026 was $107.20 Mil.

SELLAS Life Sciences Group's quarterly Ending Cash Position increased from Sep. 2025 ($44.42 Mil) to Dec. 2025 ($71.89 Mil) and increased from Dec. 2025 ($71.89 Mil) to Mar. 2026 ($107.20 Mil).

SELLAS Life Sciences Group's annual Ending Cash Position increased from Dec. 2023 ($2.63 Mil) to Dec. 2024 ($13.99 Mil) and increased from Dec. 2024 ($13.99 Mil) to Dec. 2025 ($71.89 Mil).

SELLAS Life Sciences Group Ending Cash Position Related Terms

SELLAS Life Sciences Group Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SELLAS Life Sciences Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group Ending Cash Position Chart

SELLAS Life Sciences Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.46 17.23 2.63 13.99 71.89

SELLAS Life Sciences Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.50 25.40 44.42 71.89 107.20
SLS
25GF Score
SELLAS Life Sciences Group Inc SLS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SELLAS Life Sciences Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SELLAS Life Sciences Group's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=13.986+57.907
=71.89

SELLAS Life Sciences Group's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=71.893+35.304
=107.20

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $107.20 Mil mean?
SELLAS Life Sciences Group (SLS) has a Ending Cash Position of $107.20 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SELLAS Life Sciences Group and its competitors.
Is SELLAS Life Sciences Group's Ending Cash Position too high?
SELLAS Life Sciences Group's current Ending Cash Position is $107.20 Mil. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Ending Cash Position compare to MBX and BHVN?
SELLAS Life Sciences Group's Ending Cash Position of $107.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current Ending Cash Position is $107.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Ending Cash Position of $107.20 Mil. The current Ending Cash Position is $107.20 Mil. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Ending Cash Position is $107.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Other Exchanges RXK3:Germany
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for SLS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.95
Price